Supercharged immune cells take on Hard-to-Treat myeloma
Disease control
Completed
This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to prior therapies. It combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and standard chemotherapy. The main goal is to…
Phase: PHASE1 • Sponsor: Elvira Umyarova • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC